Publications by authors named "Dougal McClean"

Claim this Profile
S
Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.
Stefan Verheye, Bert Ferdinande, Johan Bennett, Rodolfo Staico, Seif El-Jack, Dougal McClean

Catheter Cardiovasc Interv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in the Detection, Management and 30-Day Outcomes of Spontaneous Coronary Artery Dissection: A Six-Year, New Zealand Centre Experience.
Cameron P McAlister, Ma Yi, Philip D Adamson, Richard W Troughton, Maxine Rhodes, Dougal R McClean

Heart Lung Circ· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A myeloperoxidase precursor, pro-myeloperoxidase, is present in human plasma and elevated in cardiovascular disease patients.
Irada S Khalilova, Nina Dickerhof, Tessa J Mocatta, Catriona J Bhagra, Dougal R McClean

PLoS One· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds.
Carlos Collet, Bernard Chevalier, Angel Cequier, Jean Fajadet, Marcello Dominici, Dougal McClean

JACC Cardiovasc Imaging· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Utility of Contrast Medium Fractional Flow Reserve in Functional Assessment Of Coronary Disease in Daily Practice.
Pieter Van Wyk, Aniket Puri, James Blake, John Michael Elliott, Dougal McClean

Heart Lung Circ· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Assessment of Tissue Precursors and Progression of Coronary Calcification Analyzed by Fusion of IVUS and OCT: 5-Year Follow-Up of Scaffolded and Nonscaffolded Arteries.
Yaping Zeng, Hiroki Tateishi, Rafael Cavalcante, Erhan Tenekecioglu, Pannipa Suwannasom, Dougal R McClean

JACC Cardiovasc Imaging· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography: Insights From the ABSORB Cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Yoshinobu Onuma, Maik J Grundeken, Shimpei Nakatani, Taku Asano, Yohei Sotomi, Dougal McClean

Circ Cardiovasc Interv· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy.
Yoshinobu Onuma, Carlos Collet, Robert-Jan van Geuns, Bernard de Bruyne, Evald Christiansen, Dougal McClean

Eur Heart J Cardiovasc Imaging· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current practices of Asia-Pacific cardiologists in the utilization of bioresorbable scaffolds.
B B Chanana, Praveen Chandra, Jack Jun Cheng, Ron Dick, Hyeon-Cheol Gwon, Dougal McClean

Int J Cardiol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Patrick W Serruys, Bernard Chevalier, Yohei Sotomi, Angel Cequier, Didier Carrié, Dougal McClean

Lancet· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a crystalline sirolimus-eluting coronary stent with a bioabsorbable polymer designed for rapid dissolution: two-year outcomes from the DESSOLVE I and II trials.
William Wijns, Maarten Jan Suttorp, Leszek Zagozdzon, Marie-Claude Morice, Dougal McClean

EuroIntervention· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Patrick W Serruys, John Ormiston, Robert-Jan van Geuns, Bernard de Bruyne, Dariusz Dudek, Dougal McClean

J Am Coll Cardiol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
Christos V Bourantas, Patrick W Serruys, Shimpei Nakatani, Yao-Jun Zhang, Vasim Farooq, Dougal McClean

EuroIntervention· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome with Elevated Cardiac Troponin but Non-obstructive Coronary Disease on Angiography.
Sally Aldous, John Elliott, Dougal McClean, Aniket Puri, A Mark Richards

Heart Lung Circ· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
Yuki Ishibashi, Takashi Muramatsu, Shimpei Nakatani, Yohei Sotomi, Pannipa Suwannasom, Dougal McClean

JACC Cardiovasc Interv· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial.
Christos V Bourantas, Vasim Farooq, Yaojun Zhang, Takashi Muramatsu, Bill D Gogas, Dougal McClean

EuroIntervention· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Yoshinobu Onuma, Patrick W Serruys, Takashi Muramatsu, Shimpei Nakatani, Robert-Jan van Geuns, Dougal McClean

JACC Cardiovasc Interv· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Patrick W Serruys, Yoshinobu Onuma, Hector M Garcia-Garcia, Takashi Muramatsu, Robert-Jan van Geuns, Dougal McClean

EuroIntervention· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Congestion bleeding of the head and neck following myocardial infarction.
Caroline Mahon, Paul Maurice, Dougal McClean

N Z Med J· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Koen Nieman, Patrick W Serruys, Yoshinobu Onuma, Robert-Jan van Geuns, Hector M Garcia-Garcia, Dougal McClean

J Am Coll Cardiol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.
Bill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, Yoshinobu Onuma, Takashi Muramatsu, Dougal McClean

EuroIntervention· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study.
Ian Buysschaert, Christophe L Dubois, Joseph Dens, John Ormiston, Stephen Worthley, Dougal McClean

EuroIntervention· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated delivery system: the DIRECT study.
Mark Webster, Scott Harding, Dougal McClean, Warwick Jaffe, John Ormiston

EuroIntervention· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous two-vessel very-late stent thrombosis of everolimus-eluting stents.
Aniket Puri, Ramkrishna Saireddy, Dougal McClean

J Invasive Cardiol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
Roberto Diletti, Vasim Farooq, Chrysafios Girasis, Christos Bourantas, Yoshinobu Onuma, Dougal McClean

Heart· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis